Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib Combine With Endocrine Therapy and Anti-HER2 Therapy in HR Positive and HER2 Positive Advanced Breast Cancer
NCT05969184Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Dec 2021
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib and trastuzumab in breast cancer, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression free survival at 2 years. Started Dec 2021; status: completed.
02
Drugs
palbociclibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05969184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05969184.